All In Biotech

Drug Trial Radar · NCT06588153

A Study for the Evaluation of Efficacy and Safety of Prolia® in Participants With Glucocorticoid-induced Osteoporosis in Mainland China

A Phase 4 Single-arm Open-label Study for the Efficacy and Safety of Prolia® in Participants With Glucocorticoid-induced Osteoporosis in Mainland China

Last checked: Nov 20, 2026Latest source record: May 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

102

Actual

Start

May 24, 2025

Primary completion

Apr 27, 2027

Study completion Apr 27, 2027

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
First posted
Sep 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main objective of this study is to evaluate the efficacy of Prolia® in improving bone mass density (BMD) of lumbar spine at month 12.

Conditions

  • Glucocorticoid-induced Osteoporosis

Interventions

  • Prolia®Drug

    Subcutaneous (SC) injection in pre-filled syringe.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline in Lumbar Spine BMD PercentageTime frame: At 12 months

Locations

16 sites in 1 country. Site status is shown where the registry gives one.

  • Sichuan Provincial Peoples Hospital

    Chengdu, China

  • Beijing Friendship Hospital, Capital Medical University

    Beijing, Beijing Municipality, China

  • Guangzhou First Peoples Hospital

    Guangzhou, Guangdong, China

  • Nanfang Hospital Southern Medical University

    Guangzhou, Guangdong, China

  • Shenzhen Peoples Hospital

    Shenzhen, Guangdong, China

  • The First Affiliated Hospital of Henan University of Science and Technology

    Luoyang, Henan, China

  • Union Hospital Tongji Medical College Huazhong University of Science and Technology

    Wuhan, Hubei, China

  • The First Peoples Hospital of Changzhou

    Changzhou, Jiangsu, China

  • Huaian First Peoples Hospital

    Huaian, Jiangsu, China

  • Affiliated Hospital of Nantong University

    Nantong, Jiangsu, China

  • Pingxiang Peoples Hospital

    Pingxiang, Jiangxi, China

  • The First Bethune Hospital of Jilin University

    Changchun, Jilin, China

  • The First Affiliated Hospital of Xi An Jiaotong University

    Xi'an, Shaanxi, China

  • Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine

    Shanghai, Shanghai Municipality, China

  • First Hospital of Shanxi Medical University

    Taiyuan, Shanxi, China

  • Zhejiang Provincial Peoples Hospital

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.